Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label study of Klisyri for superficial basal cell carcinoma
2023-505971-66-00Phase 3Authorised
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tirbanibulin in basal cell carcinoma (BCC), sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoint: Complete remission at end of treatment. Planned start Nov 2023; status: authorised.
02
Drugs
tirbanibulin
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2023-505971-66-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505971-66-00.